Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Journal Title: Chronic Obstructive Pulmonary Disease: Open Access - Year 2017, Vol 2, Issue 1

Abstract

Background: Acute exacerbation (AE) is known as a leading cause of morbidity and mortality in chronic fibrosing group includes idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). There is no standardizes drug therapy with comparative studies. The clinical application of recombinant human soluble thrombomodulin (rhTM) has recently been expected against AE-IPF/NSIP, however, the impact of rhTM remains unestablished. Thus, this review assessed the impact of rhTM on mortality in patients with AE-IPF/NSIP. Methods: PubMED database was investigated for studies in English on May 2017 by two independent reviewers. The investigated period was restricted to previous 10 years. Studies was included adults with AE of IPF or idiopathic interstitial pneumonias, and treatment with thrombomodulin. Key data on study design, patient characteristics, outcome measures and adverse events were extracted for the review. We pooled mortality using random-effects meta-analysis Results: Three prospective and two retrospective studies were included. The five studies recruited a total of 77 patients receiving rhTM treatment (rhTM group). Corticosteroid therapy was examined in all studies for both rhTM groups and non-rhTM group. Mortality at 28 days or one month was evaluated in all three prospective studies, and was significantly lower in the rhTM group than in nonrhTM group. The pooled 1-month mortality was significantly lower in rhTM group (Odds Ratio (OR): 0.25 (95% CI, 0.08-0.77)). Mortality at 3 months was also lower in rhTM group. In patients with AE-IPF/NSIP, rhTM administration was of significant prognostic value of 3-month mortality by univariate analysis and by multivariate analysis. Two retrospective studies reported adverse effect in rhTM group and/or non-rhTM group. Conclusion: In this study, a decline in mortality was confirmed when rhTM was administered in treating AE-IPF/ NSIP, in conjunction with steroid therapy and immunosuppressive drugs. It indicated a possibility of rhTM administration being effective against AE-IPF/NSIP.

Authors and Affiliations

Kenji Tsushima

Keywords

Related Articles

Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Background: Acute exacerbation (AE) is known as a leading cause of morbidity and mortality in chronic fibrosing group includes idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). There is n...

Minute lesions of alveolar damages in lungs of patients with stable chronic obstructive pulmonary disease

Objective: To reveal the mechanism underlying recruitment of neutrophils in chronic obstructive pulmonary disease (COPD) lungs and to investigate the role of minute lesions of alveolar damage (MLADs) in emphysema develop...

Relation between Cor Pulmonale Status and Metrics of Six Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease: A Cross Sectional Study

Background: Cor pulmonale is a complication of chronic obstructive pulmonary disease (COPD). The use of the six minute walk test (6MWT) to discriminate between COPD patients with and without cor pulmonale remains unclear...

Acute Effects of Inspiratory Muscle Training on Pulmonary Arterial Pressure,Cardiac Output and Pulmonary Arterial Saturation Derived Oxygen Cost of Breathing

Respiration and respiratory maneuvers affect cardiac output. Inspiratory muscle training (IMT) increases the negative thoracic pressure, which could have an impact on intra-thoracic hemodynamics and thereby influence the...

COPD Treatment in Real Life and Randomized Controlled Trials: Is There Any Difference between Both Settings?

In the last decade, for treatment of patients with chronic obstructive pulmonary disease (COPD) a myriad of new medications, mostly administered in new inhalation devices were introduced on the market. In addition, All,...

Download PDF file
  • EP ID EP304124
  • DOI 10.21767/2572-5548.100024
  • Views 40
  • Downloads 0

How To Cite

Kenji Tsushima (2017). Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Chronic Obstructive Pulmonary Disease: Open Access, 2(1), 1-5. https://europub.co.uk./articles/-A-304124